Finanzas de Calidi Biotherapeutics Inc (CLDI)CLDICalidi Biotherapeutics Inc

Evaluating the bottom line, Calidi Biotherapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -957.89%, provide a clear picture of how effectively CLDI converts its operational activities into shareholder value.

In the context of the broader market, CLDI competes directly with industry leaders such as REVB and DCOY. With a market capitalization of $2.51M, it holds a significant position in the sector. When comparing efficiency, CLDI's gross margin of N/A stands against REVB's N/A and DCOY's 100.00%. Such benchmarking helps identify whether Calidi Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

Calidi Biotherapeutics has reported consistent net losses, with a net income of -4,417,000 USD for Q1 2026 and -4,160,000 USD for Q2 2026. The gross profit has been negative in recent quarters, indicating ongoing financial struggles.